Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.68 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.64 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.55 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | RPA1 | P27694 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731115 | 0.88 | P4HTM (0.64) | MAP4K4EGLN1P4HTMP4HA1MIF | |
| SCHEMBL71034 | 0.84 | HIF1A (0.55) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL29929320 | 0.84 | HIF1A (0.55) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL4558391 | 0.84 | MAP4K4 (0.55) | MAP4K4EGLN1P4HTMKMOP4HA1 | |
| SCHEMBL211889 | 0.84 | P4HTM (0.59) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL11044314 | 0.82 | P4HTM (0.53) | MAP4K4EGLN1P4HTMP4HA1MIF | |
| Hydrochloric Acid SCHEMBL28470042 | 0.82 | HIF1A (0.54) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL28654391 | 0.82 | P4HTM (0.70) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| Hydrochloric Acid SCHEMBL1828697 | 0.82 | P4HTM (0.57) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL31474568 | 0.82 | P4HTM (0.57) | MAP4K4P4HTMP4HA1MIFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| CN-1678591-A | Novel carboxamide compounds having MCH-antagonistic action, pharmaceutical preparations comprising said compounds and process for their preparation | BOEHRINGER INGELHEIM INT (DE) | 2005-10-05 | — | — | CN | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-109180671-A | Imino group thiadiazine dioxide derivative and application thereof | 广东东阳光药业有限公司 | 2019-01-11 | — | — | CN | disclosed |
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| CN-1678591-A | Novel carboxamide compounds having MCH-antagonistic action, pharmaceutical preparations comprising said compounds and process for their preparation | BOEHRINGER INGELHEIM INT (DE) | 2005-10-05 | — | — | CN | disclosed |
| EP-1539158-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534689-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004024702-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004006922-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-1984004302-A1 | SUBSTITUTED PICOLINIC ACIDS, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | MAP4K4 2520/4885EGLN1 478/4885P4HTM 1548/4885 |
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | MAP4K4 3265/4885EGLN1 1749/4885P4HTM 2447/4885 |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | MAP4K4 944/4885EGLN1 1644/4885P4HTM 642/4885 |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | LDLR, NR1H2, NR1H3 | MAP4K4 2721/4885EGLN1 1274/4885P4HTM 789/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | MAP4K4 3228/4885EGLN1 1737/4885P4HTM 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.